Zach White, 23, and Elise Scalfani, 26, open up to PEOPLE about connecting through social media about their shared type 1 ...

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Insulet Corp (PODD) surpasses $2 billion in revenue with strong Omnipod 5 demand, while navigating pricing headwinds and ...

The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external ...

For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%.

For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total ...